Expression of PACAP, and PACAP type 1 (PAC(1)) receptor mRNA during development of the mouse embryo

W J Sheward, E M Lutz, A J Copp, A J Harmar

Research output: Contribution to journalArticlepeer-review


Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) have been reported to have a number of neurotrophic effects. We have examined the expression of mRNA for PACAP and PACAP type 1 (PAC(1)) receptor in the mouse embryo by in situ hybridization and the effects of PACAP and VIP on the growth of mouse embryos in vitro. Although we were unable to detect gross effects of either peptide on the growth rates of embryos maintained in culture, mRNAs for both PAC(1) receptor and PACAP peptide were present in the nervous system from day 9.5 of embryonic development. PAC(1) receptor mRNA was most abundant in the neural tube and the rhombencephalon and was present also in the dorsal root and trigeminal ganglia and the sympathetic chain. The distribution of mRNA for the PACAP peptide overlapped in part with that of the receptor, but was more extensively distributed in the rhombencephalon and in the developing hypothalamus. Within the neural tube, PAC(1) receptor mRNA was located in the roof and floor plates, while the distribution of PACAP peptide mRNA was more complex, being located in two columns of cells in the ventromedial neural tube (consistent with the position of developing autonomic motor neurons) and in cells in the dorsolateral neural tube. These data are concordant with a role for PACAP or a related peptide in neural development. (C) 1998 Elsevier Science B.V. All rights reserved.

Original languageEnglish
Pages (from-to)245-253
Number of pages9
JournalDevelopmental brain research
Issue number2
Publication statusPublished - 8 Aug 1998


Dive into the research topics of 'Expression of PACAP, and PACAP type 1 (PAC(1)) receptor mRNA during development of the mouse embryo'. Together they form a unique fingerprint.

Cite this